CEO Fred Aslan was paid $6,671,215 in fiscal year 2025, ↓ down 14.8% from fiscal year 2024 (SEC filing 0001193125-26-330563 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$6,671,215 ↓ Fred Aslan total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ARTV's next annual pay disclosure, estimated November 7, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Fred Aslan | $665,000 | $0 | $5,455,700 | $0 | $536,281 | $0 | $14,234 | $6,671,215 |
| Chief Executive Officer | ||||||||
| Jennifer Bush | 520,000 | 0 | 697,501 | 0 | 304,980 | 0 | 14,234 | 1,536,715 |
| Chief Operating Officer, Chief Legal Officer and Compliance Officer | ||||||||
| Christopher Horan | 490,000 | 0 | 638,236 | 0 | 287,385 | 0 | 234 | 1,415,855 |
| Chief Technical Operations Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Fred Aslan | $6,671,215 | $7,827,554 | $1,107,533 | ↓ −1,156,339 |
| Jennifer Bush | 1,536,715 | 1,505,605 | 725,591 | ↑ +31,110 |
| Christopher Horan | 1,415,855 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Artiva Biotherapeutics's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ARTV reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
This is the complete answer, not a partial one — the list is never padded.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Alison Moore, Ph.D | Independent Director | $71,390 |
| Brian Daniels, M.D | Independent Director | $117,357 |
| Daniel Baker, M.D | Independent Director | $180,527 |
| Diego Miralles, M.D | Independent Director | $71,390 |
| Elizabeth Hougen | Independent Director | $71,390 |
| Laura Bessen, M.D | Former director (through FY2025) | $28,410 |
| Laura Stoppel, Ph.D | Independent Director | $71,249 |
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Horan | RSU | 1,616 | — | $6,933 |
| Fred Aslan | RSU | 76,002 | — | 326,049 |
| Fred Aslan | RSU | 13,776 | — | 59,099 |
| Jennifer Bush | RSU | 7,400 | — | 31,746 |
| Fred Aslan | RSU | 148,958 | — | 639,030 |
| Fred Aslan | RSU | 566,470 | — | 2,430,156 |
| Fred Aslan | RSU | 212,888 | — | 913,290 |
| Fred Aslan | RSU | 162,500 | — | 697,125 |
| Christopher Horan | RSU | 88,436 | — | 379,390 |
| Jennifer Bush | RSU | 70,405 | — | 302,037 |
| Jennifer Bush | RSU | 60,371 | — | 258,992 |
| Jennifer Bush | RSU | 3,426 | — | 14,698 |
| Christopher Horan | RSU | 48,750 | — | 209,138 |
| Jennifer Bush | RSU | 34,375 | — | 147,469 |
| Christopher Horan | RSU | 17,188 | — | 73,737 |
| Christopher Horan | RSU | 13,683 | — | 58,700 |
| Jennifer Bush | RSU | 13,680 | — | 58,687 |
| Christopher Horan | RSU | 3,421 | — | 14,676 |
The company seeks to motivate and reward executives for achievements relative to corporate goals and expectations. Equity awards are considered an integral component of the compensation program to secure and retain services and align interests with stockholders.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | Dodd-Frank Act-compliant clawback policy implemented as required by SEC rules; Section 304 of Sarbanes-Oxley Act applies. |
| Anti-hedging | Insider Trading Policy prohibits directors, officers, consultants, and employees from engaging in derivatives securities or hedging transactions. |
| Anti-pledging | Insider Trading Policy prohibits pledging securities as collateral for a loan without prior Board approval and pre-clearance from the Chief Legal Officer. |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-09-08 | — | — | — | — | — |
| 2025 | 2025-06-24 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-09-08 | —a |
| 2025 | 2025-06-24 | —b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel Baker, M.DIndependent · Compensation · Nominating and Corporate Governance (Chair) · Clinical Development · Commercial Planning | $51,898 | — | $128,629 | — | — | $180,527 |
| Brian Daniels, M.DIndependent · Clinical Development Committee (Chair) · Compensation Committee (Chair) · Nominating and Corporate Governance Committee · Philanthropic Committee | 100,967 | — | 16,390 | — | — | 117,357 |
| Diego Miralles, M.DIndependent | 55,000 | — | 16,390 | — | — | 71,390 |
| Elizabeth HougenIndependent · Audit (Chair) | 55,000 | — | 16,390 | — | — | 71,390 |
| Alison Moore, Ph.DIndependent · Technical Operations (Chair) | 55,000 | — | 16,390 | — | — | 71,390 |
| Laura Stoppel, Ph.DIndependent · Clinical Development Committee · Audit | 54,859 | — | 16,390 | — | — | 71,249 |
| Laura Bessen, M.DIndependent · Departed during FY | 28,410 | — | 0 | — | — | 28,410 |
| Fred Aslan, M.DEmployee director | — | — | — | — | — | 0 |
| Elaine SorgIndependent · Audit Committee · Commercial Planning Committee (Chair) | — | — | — | — | — | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 7,500 / 12,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $401,134 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $401,134 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Artiva Biotherapeutics | 2025 | Fred Aslan | $665,000 | $5,455,700 | $0 | $536,281 | $6,671,215 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Fred Aslan | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Summary Compensation Table” · page 34. As printed: 6,671,215. Filing ↗machine: r2 · c25 · span 611443–611452 |
| 2 | Section 01, Jennifer Bush | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Summary Compensation Table” · page 34. As printed: 1,536,715. Filing ↗machine: r4 · c25 · span 630137–630146 |
| 3 | Section 01, Christopher Horan | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Summary Compensation Table” · page 34. As printed: 1,415,855. Filing ↗machine: r6 · c25 · span 649122–649131 |
| 4 | Section 07, pay ratio | 10-K/A | 2026-04-30 | 0001193125-26-197115 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Section 08, Daniel Baker, M.D | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: 180,527. Filing ↗machine: span 976196–976405 |
| 6 | Section 08, Brian Daniels, M.D | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: 117,357. Filing ↗machine: span 952861–953070 |
| 7 | Section 08, Diego Miralles, M.D | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: 71,390. Filing ↗machine: span 962226–962434 |
| 8 | Section 08, Elizabeth Hougen | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: 71,390. Filing ↗machine: span 957462–957670 |
| 9 | Section 08, Alison Moore, Ph.D | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: 71,390. Filing ↗machine: span 966829–967037 |
| 10 | Section 08, Laura Stoppel, Ph.D | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: 71,249. Filing ↗machine: span 971593–971801 |
| 11 | Section 08, Laura Bessen, M.D | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: 28,410. Filing ↗machine: span 945498–945706 |
| 12 | Section 08, Fred Aslan, M.D | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 13 | Section 08, Elaine Sorg | DEF 14A | 2026-08-03 | 0001193125-26-330563 | Section “Director Compensation”. As printed: —. Filing ↗ |
| 14 | Section 06, 2026 vote | Form 8-K | 2026-09-11 | 0001193125-26-389308 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 15 | Section 06, 2025 vote | Form 8-K | 2025-06-25 | 0000950170-25-089942 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 16 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 17 | Section 09b board cost (computed) | Computed | — | — | Cash 401,134 + equity 0 + all other 0 = 401,134, summed across the director compensation table rows.machine: formula: Σ = 401,134 |
| 18 | Artiva Biotherapeutics (subject), Section 10b CEO total | DEF 14A | 2026-08-03 | 0001193125-26-330563 | CEO total compensation as printed in Artiva Biotherapeutics's own proxy. As printed: 6,671,215. Filing ↗machine: r2 · c25 · span 611443–611452 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.